Verdiva Bio

📍 London, United Kingdom👥 28 employees💰 Last funded Jan 2025
Biotechnology Research🌐 verdivabio.com
Website LinkedIn
Verdiva Bio is committed to developing next-generation therapies to help people living with obesity, cardiometabolic disorders, and related complications achieve better outcomes via more patient-friendly therapeutic options. Our most advanced therapy is VRB-101, an oral GLP-1 peptide in clinical development that has demonstrated best-in-class efficacy potential in a phase 1 study in Australia, which also confirmed the viability of once-weekly dosing. We are also developing a portfolio of amylin molecules, including oral and subcutaneous agonists, and other undisclosed programs that offer the potential for enhanced efficacy, improved tolerability, and healthier weight loss. The Verdiva team will harness the emerging science in gut-brain biology and leverage their history of successful drug development to advance novel therapeutic options aiming to transform the lives of millions living with obesity worldwide. For more information, please visit www.verdivabio.com.
1
Total investors
0
Early stage
0
Mid stage
0
Late stage
—
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
Netherlands
1
Frequently asked questions
Who invested in Verdiva Bio?
Verdiva Bio has 1 investors on record on gritt.io.
When did Verdiva Bio last raise funding?
The most recent investment in Verdiva Bio recorded on gritt.io was in January 2025.
What industry is Verdiva Bio in?
Verdiva Bio operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Verdiva Bio based?
Verdiva Bio is headquartered in London, United Kingdom.